Gujarat Kidney and Super Speciality Ltd
Announcement of Quarterly and Annual Results for the Financial year ended on 31.03.2026
RESULTS
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 28 May 2026, 10:43 PM IST · BSE ID: 3ed3f0e4-19d9-4dc2-9224-46bc36b00d62
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its full-year financial results, showing a profit increase, but postponed its CEO appointment.
🤖 AI Summary
- Gujarat Kidney and Super Speciality Ltd approved audited financial results for the year ended March 31, 2026.
- Profit After Tax for FY26 was Rs. 990.14 Lacs, compared to Rs. 910.90 Lacs in FY25.
- Total Income for the year ended March 31, 2026, stood at Rs. 4,059.47 Lacs.
- The Board deferred the appointment of a CEO and announced a postal ballot for variation in IPO objects.
- Mr. Siddharth Atulbhai Shah was appointed as Internal Auditor for FY2026-27, and SPANJ & Associates as Secretarial Auditor for five years.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Profit After Tax (FY26)
990.14 Lacs
8.70%
Profit After Tax (FY25)
910.90 Lacs
Revenue From Operations (FY26)
4,010.02 Lacs
14.03%
Revenue From Operations (FY25)
3,516.70 Lacs
Total Equity (March 31, 2026)
24,645.86 Lacs
Total Equity (March 31, 2025)
2,541.56 Lacs
🏢 How This Affects the Company
The variation in IPO objects via postal ballot could indicate a strategic shift in the company's intended business focus or future plans that align with new capital allocation.
The company reported an increase in Profit After Tax to Rs. 990.14 Lacs for FY26, supporting overall equity growth to Rs. 24,645.86 Lacs.
The appointment of new internal and secretarial auditors for FY226-27 and for five consecutive years respectively enhances the company's governance framework.
Deferring the CEO appointment introduces uncertainty regarding leadership and strategic direction in the near term.
👥 What This Means For Shareholders
✅
Action Required
Shareholders will be required to participate in a postal ballot to approve a Special Resolution for variation in the Objects of IPO.
👤
Who Is Affected
All shareholders will be affected by the postal ballot, as changes to the Objects of IPO could redefine the company's future business focus and capital deployment strategies.
🔍
Management Signal
Management is signaling a re-evaluation of its strategic priorities by proposing a variation in IPO objects and deferring the CEO appointment.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Outcome of the postal ballot on variation of IPO objects.
Announcement regarding the appointment of a CEO.
Detailed reports or explanations for the significant increase in Other Non-current assets.
MEDIUM RISK
The deferral of CEO appointment and proposed IPO object variation introduce strategic and leadership uncertainties.
💡 Investor Takeaway
Gujarat Kidney and Super Speciality Ltd reported a Profit After Tax of Rs. 990.14 Lacs for FY26, up from Rs. 910.90 Lacs in FY25. Total Income reached Rs. 4,059.47 Lacs for the year. The Board deferred the appointment of a CEO.
⚖️ Strengths & Concerns
✅ Positives
- Profit After Tax for FY26 increased to Rs. 990.14 Lacs from Rs. 910.90 Lacs in FY25, indicating annual earnings growth.
- Total Equity significantly increased to Rs. 24,645.86 Lacs as of March 31, 2026, from Rs. 2,541.56 Lacs in FY25.
⚠️ Concerns
- Current financial liabilities for borrowings increased to Rs. 1,296.20 Lacs as of March 31, 2026, from Rs. 95.53 Lacs in FY25.
- The deferral of the CEO appointment indicates a temporary lack of clarity in top-level management leadership.
📅 Company Track Record
A previous filing on March 13, 2026, for the second quarter reported a profit increase of 69.5% YoY to Rs. 389.98 Lacs, but also noted a surge in short-term debt of 1,229% to Rs. 1,270.71 Lacs, indicating a pattern of increasing debt alongside profit growth.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Gujarat Kidney's Profit After Tax for the year ended March 31, 2026?
Gujarat Kidney and Super Speciality Ltd reported a Profit After Tax of Rs. 990.14 Lacs for the year ended March 31, 2026.
What was Gujarat Kidney's Total Income for FY26?
The Total Income for Gujarat Kidney and Super Speciality Ltd for the year ended March 31, 2026, was Rs. 4,059.47 Lacs.
What significant board decisions were made by Gujarat Kidney on May 28, 2026?
The Board approved audited financial results, deferred the CEO appointment, and decided to conduct a postal ballot for variation in IPO objects.
Who was appointed as the Internal Auditor for Gujarat Kidney for FY2026-27?
Mr. Siddharth Atulbhai Shah was appointed as the Internal Auditor of Gujarat Kidney and Super Speciality Ltd for the Financial Year 2026-27.
Questions based on this BSE filing only. For information purposes.